



CASE: LA0112 NP

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Burton Rodney
Type or print name

Signature

Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

ART UNIT: 1626

TIMUR GUNGOR, ET AL.

EXAMINER: STOCKTON, LAURA LYNNE

APPLICATION NO: 10/775,742

FILED: 02/10/2004

FOR: NOVEL THIAZOLIDINE COMPOUNDS AS CALCIUM
SENSING RECEPTOR MODULATORS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

DECLARATION OF ZHENGPING MA

To the Commissioner for Patents and Trademarks:

ZHENGPING MA DECLARES AS FOLLOWS:

1. She has a Master's degree in Biology and acquainted with testing of chemical compounds for activity as a modulator of the calcium sensing receptor employing test protocol.
2. She was employed at Bristol-Myers Squibb Company under the supervision of Dr. Ramakrishna Seethala.

BEST AVAILABLE COPY

3. That prior to October 22, 2001, she received a sample of the compound of Example 1 of the subject application which was sent from Dr. Ramakrishna Seethala, Department of Metabolic Diseases, Age Related Diseases and Bone Biology for testing of such compound as a modulator of the calcium receptor.

4. In Notebook No. 49,513, page 079-081, 083 and 084 (ATTACHMENT K through Q, including cover page and table of contents), Zhengping Ma, under the supervision of Dr. Ramakrishna Seethala, recorded experiments concerning the testing of the compound of Example 1 as a modulator of the calcium sensing receptor.

All of Notebook No. 49,513, pages 079-081, 083 and 084 were signed by Zhengping Ma and witnessed by Yong Quan prior to October 22, 2001.

5. The testing of the compound of Example 1 for its activity in modulating the calcium sensing receptor was carried out as follows:

Calcium Receptor Inhibitor Assay Methods:

Inhibition of intracellular calcium:

Calcilytic activity was measured in human TT cells (ATCC No. CRL-1083) by determining the IC₅₀ of the test compound for blocking increases in intracellular Ca²⁺ by extracellular Ca²⁺ (as agonist of the receptor). Intracellular Ca²⁺ was measured using Fluo3,AM (Molecular probes, # F-1242) as indicator dye. Intracellular Ca²⁺ increase was measured with extracellular Ca²⁺ from 0.5 to 5 mM in Fluorescence Imaging Plate Reader (FLIPR) (Molecular Devices).

The Ca²⁺ receptor inhibitor assay procedure is as follows: TT cells were maintained in T-150 flasks in cell growth medium (F-12K Nutrition Media (Gibco 211270-022) with 10% heat inactivated FBS, and 1x Glutamax) in 5% CO₂:95% air at 37°C to 90% confluency. The medium was removed, the cell monolayer was washed with phosphate buffered saline (PBS), incubated with 0.05% trypsin at 37°C for 2 minutes and the cells were dispensed by agitation. Cells from 2 flasks were pooled and centrifuged (200xg). The cell pellet was suspended in cell growth medium. Cells were plated 30,000 cells/well for 2 days, or 24,000 cells/well for 3 days in 96-well black view plates

(Falcon, VWR#624-06-468) and incubated in 5% CO₂:95% air at 37°C. Cell medium was aspirated, and cells were loaded with Fluo3 (Molecular Probes, 50 µg dissolved in 25 µl DMSO, 50 µl 20% Pluronic Acid) in base buffer (10 mM HEPES buffer containing 1x Hank's salt, 0.1% BSA, 0.05% D-glucose, 0.8 mM CaCl₂) or 1 hour in a 37°C incubator. After incubation, loading buffer was aspirated and 120 ul/well base buffer was added.

Drug plates were prepared in base buffer and loaded into FLIPR. 30 ul from drug plate was added to the cell assay plate and fluorescence signals were read in FLIPR. Drug plate was replaced with CaCl₂ plate in FLIPR plate draw and 30 ul CaCl₂ (1.7 mM final for IC₅₀s, or 2.0 mM for screening) was added into cell plate by FLIPR. The fluorescence signal was measured by reading at 1 second intervals for 30 seconds and at 3 second intervals for the next 150 seconds. Calcilytic activity of the compounds was measured by their ability to block, in a concentration dependent manner (half-log concentrations in triplicate), the intracellular Ca²⁺ level by extracellular 1.7 mM Ca²⁺. The data was processed by ActivityBase (IDDBS) and the IC₅₀ values are determined by protocols developed.

6. A summary of the test results obtained by Zhengping Ma (prior to October 22, 2001) is set out in a summary sheet (ATTACHMENT R) prepared after October 22, 2001.

7. The actual dates of Experiments regarding the testing of the Example 1 compound recorded in Notebook No. 49,513, pages 079-081, 083 and 084 were carried out and the dates of signing by Zhengping Ma and witnessing by Yong Quan, were all prior to October 22, 2001, but have been obliterated.

8. Other non-relevant portions of Notebook No. 49,513, pages 079-081, 083 and 084 which did not relate to the testing of Example 1 compound were obliterated.

9. This Declaration is submitted prior to Final Rejection.

10. The undersigned declares further that all statements made herein of her own knowledge are true and that all statements made on information and belief are believed to be true;

and further that these statements are made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of application Serial No. 10/775,742 or any patent issued thereon.

Date:

9/20/2006

Zhengping Ma
ZHENGPING MA

BRISTOL-MYERS SQUIBB

NOTEBOOK No. 49513

Assigned to

Zhengping Ma

Subject

Department Name

Aging Research

Department Number

800 1602

Date Assigned

Date Completed

Pages Completed from

001

to

250

Continued from Notebook Number

49423

Continued in Notebook Number

51731

Caution

Proprietary and confidential information of Bristol-Myers Squibb Company.
Do not disclose or reproduce without proper written authorization.

This notebook cannot be transferred to another person

ATTACHMENT K

49513

TABLE OF CONTENTS

PROJECT OR EXPERIMENT NO.	PRODUCT OR SUBSTANCE	STUDY PERFORMED OR OBJECTIVE	PAGES
------------------------------	----------------------	------------------------------	-------

IC50s: BMS-515832-02-002, 280429, 280587	CaR response in TT cells	49513-079 49513-088
--	--------------------------	------------------------

49513

070

NOTEBOOK No.

PAGE

CaR response in TT cells

TT cells plated out at 24,000 cells/well used (see also 49513-068)

0.8 mM Ca^{2+} basal, 1.7 mM Ca^{2+} stimulation.

See also 44676-072 for basic protocol.

Plate J

BMS-515832-02-002 (μM) (A1:C6)

synthesis

	1	2	3	4	5	6
A	1.0000	0.3333	0.1111	0.0370	0.0123	0.0041
B	1.0000	0.3333	0.1111	0.0370	0.0123	0.0041
C	1.0000	0.3333	0.1111	0.0370	0.0123	0.0041

ATTACHMENT M

SIGNED

DATE

WITNESSED AND UNDERSTOOD BY

DATE

NOTESBOOK No.

PAGE

Signal Test

Continued

Site

Plate 1 ZMCA072601a_n0

Minimum 9045.6 -16.47%

Maximum 12823.2

Average 10829.4

STDEV: 738.3

	1	2	3	4	5	6
A	11194.4	10826.4	10314.4	10444.0	10192.8	9940.0
B	10764.0	11074.4	10508.0	9893.6	9832.8	9298.4
C	9922.4	11116.0	10592.8	10845.6	10831.2	10120.8

ATTACHMENT
N

SIGNED

DATE

WITNESSED AND UNDERSIGNED

DATE

Zhengyi Ma

49313


031

NOTEBOOK No.

PAGE

Continued

Z14Co072501o_n1.fid



Range = (-1000,10000)

WITNESSED AND UNDERSTOOD BY:

DATE

ATTACHMENT O

Zheng Ma

[Signature]

BRISTOL-MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE

48613 083

NOTEBOOK No. PAGE

Continued

File = D:\mzh\ZMCa972601a_n1.fid

Plate 1

Statistic = Max - Min

Start Sample = 11

End Sample = 45

Positive Scaling = On

Negative Correction = Off

Bias Value Subtract = On Spatial Uniformity Correction = On

Bias Sample = 1

	A	B	C	D	E	F	G	H
1	3.79	4.98	2.39	43.82	15.29	26.01	2.4	3.96
2	4.56	4.47	3.85	60.51	45.13	65.27	4.92	3.28
3	11.06	12.77	17.3	95.26	62.57	82.4	20.93	11.91

SIGNED

Zhenyig Ma

DATE

WITNESSED AND UNDERSTOOD BY

DATE

ATTACHMENT P

BRISTOL-MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE

49513 084

NOTEBOOK No. PAGE

Continued

Test Occasion ID: MDCaR010726-1
Protocol ID: CaR_H_IC50
Study ID: CaR
User ID: Zhengping Ma

Plate 1

Compound ID	Conc (pM)	% TL1	% TL2	% TL3	Ave % TL	StDev	PC50
BMS-515822-02-002	1.000	3.79	4.98	2.39	3.72	1.30	0.024921
	0.333	4.56	4.47	3.85	4.29	0.39	0.011111
	0.111	11.06	12.77	17.3	13.71	3.22	-1.15
	0.037	32.3	43.99	44.12	40.14	6.79	
	0.012	56.61	49.98	99.95	68.53	27.51	
	0.004	41.18	61.95	37.58	46.90	13.16	



SIGNED

Zhengping Ma

DATE


WITNESSED AND UNDERSTOOD BY

[Signature]

DATE

ATTACHMENT Q

2D	3D	Biology	CTR	HTS	Inventory	Library	Program	Property	Reaction	Reagent	Select	Info
<div style="display: flex; justify-content: space-between;"> <div> <p>BMS # BMS-515832</p> <p>Formula C₂₇ H₃₁ N₃ O S</p> <p>Submitter Chen, Ying</p> <p>Date</p> </div> <div> <p>Form 02</p> <p>Appearance off-white powder</p> <p>Chemist's Notebook 48255-108-20</p> <p>Molname</p> </div> <div> <p>Lot 002</p> <p>Location HW</p> <p>Amount (MG) 82.0</p> <p>Purity 98.1</p> </div> </div>												
<div style="display: flex; justify-content: space-between;"> <div> <p>Protocol CaR_H_IC50</p> <p>Protocol Name Ca+ Sensitive Receptor, Human species, Dose Response assay</p> <p>Parameter RECEPTOR SPECIES</p> </div> <div> <p>Version 1</p> <p>Biologist MAZH</p> <p>Assoc Value Ca SENSITIVE HUMAN</p> </div> <div> <p>Biologist's Notebook</p> <p>Protocol User Group MD PPAR</p> <p>Result Comments</p> </div> </div>												
<div style="display: flex; justify-content: space-between;"> <div> <p>Molecular Wt 445.63</p> <p>Project # 08007</p> <p>Formula Wt 518.55</p> </div> <div> <p>isomer B</p> </div> </div>												



Library Name	Test Occasion	Test Occasion Notes	Parent_Study	Condition 1	Condition 2	Condition 3	Condition 4
Alliance ID	MDCaR010726-1						
	MDCaR010726-1						
	MDCaR010726-1						
	MDCaR010809						
	MDCaR010816						
	MDCaR010816						

Study	Protocol	V	Type	AValue	</>	NValue	Units	C	C 1 AValue	C 2 AValue	C 3 AValue	C 4 AValue	Date
CaR	CaR_H_IC50	1	HILL	-1.15		-1.1500	uM						
CaR	CaR_H_IC50	1	IC50	0.024921		0.0249							
CaR	CaR_H_IC50	1	P_CONTROL	4.29		4.2900			0.33				

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER: _____**

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.